4.5 Review

Justified Concern or Exaggerated Fear: The Risk of Anaphylaxis in Percutaneous Treatment of Cystic Echinococcosis-A Systematic Literature Review

Journal

PLOS NEGLECTED TROPICAL DISEASES
Volume 5, Issue 6, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pntd.0001154

Keywords

-

Ask authors/readers for more resources

Percutaneous treatment (PT) emerged in the mid-1980s as an alternative to surgery for selected cases of abdominal cystic echinococcosis (CE). Despite its efficacy and widespread use, the puncture of echinococcal cysts is still far from being universally accepted. One of the main reasons for this reluctance is the perceived risk of anaphylaxis linked to PTs. To quantify the risk of anaphylactic reactions and lethal anaphylaxis with PT, we systematically searched MEDLINE for publications on PT of CE and reviewed the PT-related complications. After including 124 publications published between 1980 and 2010, we collected a total number of 5943 PT procedures on 5517 hepatic and non-hepatic echinococcal cysts. Overall, two cases of lethal anaphylaxis and 99 reversible anaphylactic reactions were reported. Lethal anaphylaxis occurred in 0.03% of PT procedures, corresponding to 0.04% of treated cysts, while reversible allergic reactions complicated 1.7% of PTs, corresponding to 1.8% of treated echinococcal cysts. Analysis of the literature shows that lethal anaphylaxis related to percutaneous treatment of CE is an extremely rare event and is observed no more frequently than drug-related anaphylactic side effects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Public, Environmental & Occupational Health

Comment on: Complications Associated with Initial Clinical Presentation of Cystic Echinococcosis: A 20-year Cohort Analysis

Tommaso Manciulli, Maria Teresa Giordani, Raffaella Lissandrin, Enrico Brunetti, Francesca Tamarozzi

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2020)

Editorial Material Public, Environmental & Occupational Health

Imported chronic schistosomiasis: screening and management issues

Dora Buonfrate, Francesca Tamarozzi, Federico Gobbi

JOURNAL OF TRAVEL MEDICINE (2020)

Article Immunology

Species specificity preliminary evaluation of an IL-4-based test for the differential diagnosis of human echinococcosis

Linda Petrone, Werner C. Albrich, Francesca Tamarozzi, Manuel Frischknecht, Maria Angeles Gomez-Morales, Antonella Teggi, Matthias Hoffmann, Delia Goletti

PARASITE IMMUNOLOGY (2020)

Editorial Material Parasitology

Achievements of the HERACLES Project on Cystic Echinococcosis

Adriano Casulli, Mar Siles-Lucas, Carmen Michaela Cretu, Kamena Vutova, Okan Akhan, Gulay Vural, Arantxa Cortes Ruiz, Enrico Brunetti, Francesca Tamarozzi

TRENDS IN PARASITOLOGY (2020)

Article Parasitology

The European Register of Cystic Echinococcosis, ERCE: state-of-the-art five years after its launch

Patrizia Rossi, Francesca Tamarozzi, Fabio Galati, Okan Akhan, Carmen Michaela Cretu, Kamenna Vutova, Mar Siles-Lucas, Enrico Brunetti, Adriano Casulli

PARASITES & VECTORS (2020)

Review Parasitology

Reinventing the Wheel of Echinococcus granulosus sensu lato Transmission to Humans

Francesca Tamarozzi, Peter Deplazes, Adriano Casulli

TRENDS IN PARASITOLOGY (2020)

Article Infectious Diseases

Performance of two serodiagnostic tests for loiasis in a Non-Endemic area

Federico Gobbi, Dora Buonfrate, Michel Boussinesq, Cedric B. Chesnais, Sebastien D. Pion, Ronaldo Silva, Lucia Moro, Paola Rodariid, Francesca Tamarozzi, Marco Biamonte, Zeno Bisoffi

PLOS NEGLECTED TROPICAL DISEASES (2020)

Article Medicine, General & Internal

Evaluation of Nine Commercial Serological Tests for the Diagnosis of Human Hepatic Cyst Echinococcosis and the Differential Diagnosis with Other Focal Liver Lesions: A Diagnostic Accuracy Study

Francesca Tamarozzi, Silvia Stefania Longoni, Ambra Vola, Monica Degani, Stefano Tais, Eleonora Rizzi, Marco Prato, Salvatore Scarso, Ronaldo Silva, Enrico Brunetti, Zeno Bisoffi, Francesca Perandin

Summary: The study evaluated the performance of nine commercial serological tests for diagnosing echinococcosis and found that using WB-LDBIO alone or as a third test after other non-WB tests yielded the best results. Reading results with stringent criteria may be a sensible approach.

DIAGNOSTICS (2021)

Article Biochemistry & Molecular Biology

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Emma C. Thomson, Laura E. Rosen, James G. Shepherd, Roberto Spreafico, Ana da Silva Filipe, Jason A. Wojcechowskyj, Chris Davis, Luca Piccoli, David J. Pascall, Josh Dillen, Spyros Lytras, Nadine Czudnochowski, Rajiv Shah, Marcel Meury, Natasha Jesudason, Anna De Marco, Kathy Li, Jessica Bassi, Aine O'Toole, Dora Pinto, Rachel M. Colquhoun, Katja Culap, Ben Jackson, Fabrizia Zatta, Andrew Rambaut, Stefano Jaconi, Vattipally B. Sreenu, Jay Nix, Ivy Zhang, Ruth F. Jarrett, William G. Glass, Martina Beltramello, Kyriaki Nomikou, Matteo Pizzuto, Lily Tong, Elisabetta Cameroni, Tristan Croll, Natasha Johnson, Julia Di Iulio, Arthur Wickenhagen, Alessandro Ceschi, Aoife M. Harbison, Daniel Mair, Paolo Ferrari, Katherine Smollett, Federica Sallusto, Stephen Carmichael, Christian Garzoni, Jenna Nichols, Massimo Galli, Joseph Hughes, Agostino Riva, Antonia Ho, Marco Schiuma, Malcolm G. Semple, Peter J. M. Openshaw, Elisa Fadda, J. Kenneth Baillie, John D. Chodera, Suzannah J. Rihn, Samantha J. Lycett, Herbert W. Virgin, Amalio Telenti, Davide Corti, David L. Robertson, Gyorgy Snell

Summary: SARS-CoV-2 virus can mutate and evade immunity, with mutations like N439K conferring resistance against neutralizing monoclonal antibodies and enhancing binding affinity to hACE2 receptor. Despite similar in vitro replication fitness and clinical outcomes compared to wild type, N439K mutation highlights the importance of ongoing molecular surveillance for guiding vaccine and therapeutic development and usage.
Article Multidisciplinary Sciences

Structural basis of malaria RIFIN binding by LILRB1-containing antibodies

Yiwei Chen, Kai Xu, Luca Piccoli, Mathilde Foglierini, Joshua Tan, Wenjie Jin, Jason Gorman, Yaroslav Tsybovsky, Baoshan Zhang, Boubacar Traore, Chiara Silacci-Fregni, Claudia Daubenberger, Peter D. Crompton, Roger Geiger, Federica Sallusto, Peter D. Kwong, Antonio Lanzavecchia

Summary: This study demonstrates that Plasmodium falciparum RIFINs can bind to LILRB1 through D3, and inserting receptor domains into the VH-CH1 elbow can generate novel antibodies, as shown by a naturally selected example.

NATURE (2021)

Article Multidisciplinary Sciences

Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity

Maura Garofalo, Luca Piccoli, Margherita Romeo, Maria Monica Barzago, Sara Ravasio, Mathilde Foglierini, Milos Matkovic, Jacopo Sgrignani, Raoul De Gasparo, Marco Prunotto, Luca Varani, Luisa Diomede, Olivier Michielin, Antonio Lanzavecchia, Andrea Cavalli

Summary: Systemic light chain amyloidosis (AL) is caused by the production of toxic light chains and can be fatal, yet effective treatments are often not possible due to delayed diagnosis. Here the authors show that a machine learning platform analyzing light chain somatic mutations allows the prediction of light chain toxicity to serve as a possible tool for early diagnosis of AL.

NATURE COMMUNICATIONS (2021)

Article Clinical Neurology

Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates

Florian Ingelfinger, Michael Kramer, Mirjam Lutz, Corinne C. Widmer, Luca Piccoli, Stefanie Kreutmair, Tobias Wertheimer, Mark Woodhall, Patrick Waters, Federica Sallusto, Antonio Lanzavecchia, Sarah Mundt, Burkhard Becher, Bettina Schreiner

Summary: This study suggests that myasthenia gravis (MG) may be associated with hematologic malignancies such as chronic lymphocytic leukemia (CLL). It is unclear whether the leukemic B cells are directly responsible for the autoimmune response in patients with MG and CLL. However, treatment with the anti-CD20 therapy obinutuzumab has shown potential in effectively treating AChR(+) MG.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Multidisciplinary Sciences

Neutralization, effector function and immune imprinting of Omicron variants

Amin Addetia, Luca Piccoli, James Brett Case, Young-Jun Park, Martina Beltramello, Barbara Guarino, Ha Dang, Guilherme Dias de Melo, Dora Pinto, Kaitlin Sprouse, Suzanne M. Scheaffer, Jessica Bassi, Chiara Silacci-Fregni, Francesco Muoio, Marco Dini, Lucia Vincenzetti, Rima Acosta, Daisy Johnson, Sambhavi Subramanian, Christian Saliba, Martina Giurdanella, Gloria Lombardo, Giada Leoni, Katja Culap, Carley Mcalister, Anushka Rajesh, Exequiel Dellota, Jiayi Zhou, Nisar Farhat, Dana Bohan, Julia Noack, Alex Chen, Florian A. Lempp, Joel Quispe, Lauriane Kergoat, Florence Larrous, Elisabetta Cameroni, Bradley Whitener, Olivier Giannini, Pietro Cippa, Alessandro Ceschi, Paolo Ferrari, Alessandra Franzetti-Pellanda, Maira Biggiogero, Christian Garzoni, Stephanie Zappi, Luca Bernasconi, Min Jeong Kim, Laura E. Rosen, Gretja Schnell, Nadine Czudnochowski, Fabio Benigni, Nicholas Franko, Jennifer K. Logue, Courtney Yoshiyama, Cameron Stewart, Helen Chu, Herve Bourhy, Michael A. Schmid, Lisa A. Purcell, Gyorgy Snell, Antonio Lanzavecchia, Michael S. Diamond, Davide Corti, David Veesler

Summary: The recently emerged BQ.1.1 and XBB.1.5 variants of SARS-CoV-2 have a higher affinity for the host ACE2 receptor and more efficiently promote fusion with host cell membranes compared to earlier Omicron variants. Although the neutralizing activity is reduced, vaccine-induced human plasma antibodies still cross-react with and trigger effector functions against current Omicron variants, providing a mechanism of protection against disease.

NATURE (2023)

Article Medicine, Research & Experimental

Exceptionally potent human monoclonal antibodies are effective for prophylaxis and treatment of tetanus in mice

Marco Pirazzini, Alessandro Grinzato, Davide Corti, Sonia Barbieri, Oneda Leka, Francesca Vallese, Marika Tonellato, Chiara Silacci-Fregni, Luca Piccoli, Eaazhisai Kandiah, Giampietro Schiavo, Giuseppe Zanotti, Antonio Lanzavecchia, Cesare Montecucco

Summary: The study identified two highly neutralizing tetanus neurotoxin-specific monoclonal antibodies that interfere with the binding and translocation of the neurotoxin into neurons. They were found to be effective in preventing and treating tetanus in mice, suggesting their potential for prophylactic and therapeutic use in human tetanus, and are ready for clinical trials.

JOURNAL OF CLINICAL INVESTIGATION (2021)

No Data Available